



FEB 15 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/535,624
				Int'l Filing Date	November 22, 2002
				First Named Inventor	In-Hee LEE
				Art Unit	1711
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	2393.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
/S.G./	NPL25	BELLAMY, W., <i>et al.</i> , "Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin," <i>J. Appl. Bacteriol.</i> 73:472-479, Blackwell Scientific Publications (1992)		
	NPL26	BERRIDGE, N.J., "Preparation of the Antibiotic Nisin," <i>Biochem. J.</i> 45:486-493, Portland Press (1949)		
	NPL27	BLONDELLE, S.E., and HOUGHTEN, R.A., "Hemolytic and Antimicrobial Activities of the Twenty-Four Individual Omission Analogues of Melittin," <i>Biochemistry</i> 30:4671-4678, American Chemical Society (1991)		
	NPL28	CASTEELS, P., <i>et al.</i> , "Apidaecins: antibacterial peptides from honeybees," <i>EMBO J.</i> 8:2387-2391, Oxford University Press (1989)		
	NPL29	COCIANCICH, S., <i>et al.</i> , "Novel inducible antibacterial peptides from a hemipteran insect, the sap-sucking bug <i>Pyrrhocoris apterus</i> ," <i>Biochem. J.</i> 300:567-575, Portland Press (1994)		
	NPL30	DIMARCQ, J.-L., <i>et al.</i> , "Insect immunity: expression of the two major inducible antibacterial peptides, defensin and dipterin, in <i>Phormia terranova</i> ," <i>EMBO J.</i> 9:2507-2515, Oxford University Press (1990)		
	NPL31	FRANK, R.W., <i>et al.</i> , "Amino Acid Sequences of Two Proline-rich Bactenecins," <i>J. Biol. Chem.</i> 265:18871-18874, The American Society for Biochemistry and Molecular Biology, Inc. (1990)		
	NPL32	FROHM, M., <i>et al.</i> , "The Expression of the Gene Coding for the Antibacterial Peptide LL-37 Is Induced in Human Keratinocytes during Inflammatory Disorders," <i>J. Biol. Chem.</i> 272:15258-15263, The American Society for Biochemistry and Molecular Biology, Inc. (1997)		
	NPL33	GALLO, R.L., <i>et al.</i> , "Identification of CRAMP, a Cathelin-related Antimicrobial Peptide Expressed in the Embryonic and Adult Mouse," <i>J. Biol. Chem.</i> 272:13088-13093, The American Society for Biochemistry and Molecular Biology, Inc. (1997)		
/S.G./	NPL34	GANZ, T., <i>et al.</i> , "Defensins--Natural Peptide Antibiotics of Human Neutrophils," <i>J. Clin. Invest.</i> 76:1427-1435, The American Society for Clinical Investigation, Inc. (1985)		

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/30/2008
-----------------------	--------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/535,624
				Int'l Filing Date	November 22, 2002
				First Named Inventor	In-Hee LEE
				Art Unit	1711
Sheet	2	of	3	Examiner Name	To Be Assigned
				Attorney Docket Number	2393.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
/S.G./	NPL35	GIBSON, B.W., <i>et al.</i> , "Novel Peptide Fragments Originating from PGL <sup>a</sup> and the Caerulein and Xenopsin Precursors from <i>Xenopus laevis</i> ," <i>J. Biol. Chem.</i> 261:5341-5349, The American Society of Biological Chemists, Inc. (1986)	
	NPL36	KHAN, A.A., <i>et al.</i> , "Recombinant Bactericidal/Permeability-Increasing Protein (rBPI <sub>21</sub> ) in Combination with Sulfadiazine Is Active against <i>Toxoplasma gondii</i> ," <i>Antimicrob. Agents Chemother.</i> 43:758-762, American Society for Microbiology (1999)	
	NPL37	LAMBERTY, M., <i>et al.</i> , "Solution Structures of the Antifungal Heliomicin and a Selected Variant with both Antibacterial and Antifungal Activities," <i>Biochemistry</i> 40:11995-12003, American Chemical Society (October 2001)	
	NPL38	LEMAITRE, B., <i>et al.</i> , "A recessive mutation, immune deficiency ( <i>imd</i> ), defines two distinct control pathways in the <i>Drosophila</i> host defense," <i>Proc. Natl. Acad. Sci. USA</i> 92:9465-9469, National Academy of Sciences (1995)	
	NPL39	NAKAMURA, T., <i>et al.</i> , "Tachyplesin, a Class of Antimicrobial Peptide from the Hemocytes of the Horseshoe Crab ( <i>Tachypleus tridentatus</i> )," <i>J. Biol. Chem.</i> 263:16709-16713, The American Society for Biochemistry and Molecular Biology, Inc. (1988)	
	NPL40	OPPENHEIM, F.G., <i>et al.</i> , "Histatins, a Novel Family of Histidine-rich Proteins in Human Parotid Secretion," <i>J. Biol. Chem.</i> 263:7472-7477, The American Society for Biochemistry and Molecular Biology, Inc. (1988)	
	NPL41	PARK, C.B., <i>et al.</i> , "Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II," <i>Proc. Natl. Acad. Sci. USA</i> 97:8245-8250, National Academy of Sciences (2000)	
	NPL42	SELSTED, M.E., <i>et al.</i> , "Indolicidin, a Novel Bactericidal Tridecapeptide Amide from Neutrophils," <i>J. Biol. Chem.</i> 267:4292-4295, The American Society for Biochemistry and Molecular Biology, Inc. (1992)	
	NPL43	STEINER, H., <i>et al.</i> , "Sequence and specificity of two antibacterial proteins involved in insect immunity," <i>Nature</i> 292:246-248, Macmillan Journals Ltd. (1981)	
/S.G./	NPL44	YANG, S.-T., <i>et al.</i> , "Selective cytotoxicity following Arg-to-Lys substitution in tritrypticin adopting a unique amphipathic turn structure," <i>FEBS Lett.</i> 540:229-233, Elsevier Science B.V. (April 2003)	


Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/30/2008
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet	3	of	3
-------	---	----	---

***Complete if Known***

Application Number	10/535,624
Int'l Filing Date	November 22, 2002
First Named Inventor	In-Hee LEE
Art Unit	1711
Examiner Name	<i>To Be Assigned</i>
Attorney Docket Number	2393.0010000/JUK/WBC

## NON PATENT LITERATURE DOCUMENTS

/S.G./

NPL45

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published

T2

/S.G./

NPL46

ZHAO, C., *et al.*, "Identification of a new member of the protegrin family by cDNA cloning," *FEBS Lett.* 346:285-288, Federation of European Biochemical Societies (1994)

639130 1

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/30/2008
-----------------------	--------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**

/Satyanarayan Gudibande/

Date  
Considered

01/30/2008

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/535,624
				Int'l. Filing Date	November 22, 2002
				First Named Inventor	In-Hee LEE
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	2393.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
/S.G./	NPL1	Azumi, K., <i>et al.</i> , "Halocyamines: Novel Antimicrobial Tetrapeptide-like Substances Isolated from the Hemocytes of the Solitary Ascidian <i>Halocynthia roretzi</i> ," <i>Biochem. 29</i> :159-165, American Chemical Society (1990)		
	NPL2	Azumi, K., <i>et al.</i> , "Inhibitory Effect of Halocytamine, an Antimicrobial Substance from Ascidian Hemocytes, on the Growth of Fish Viruses and Marine Bacteria," <i>Experientia. 46</i> :1066-1068, Birkhäuser Verlag (1990)		
	NPL3	Bellm, L., <i>et al.</i> , "Protegrins: New Antibiotics of Mammalian Origin," <i>Expert Opin. Investig. Drugs. 9</i> :1731-1742, Ashley Publications Ltd. (2000)		
	NPL4	Falla, T., <i>et al.</i> , "Mode of Action of the Antimicrobial Peptide Indolicidin," <i>J. Biol. Chem. 271</i> :19298-19303, The American Society for Biochemistry and Molecular Biology, Inc. (1996)		
	NPL5	Fehlbaum, P., <i>et al.</i> , "Structure-Activity Analysis of Thanatin, a 21-Residue Inducible Insect Defense Peptide with Sequence Homology to Frog Skin Antimicrobial Peptides," <i>Proc. Natl. Acad. Sci. USA. 93</i> :1221-1225, National Academy of Sciences (1996)		
	NPL6	Goraya, J., <i>et al.</i> , "Peptides with Antimicrobial Activity from Four Different Families Isolated from the Skins of the North American Frogs <i>Rana Luteiventris</i> , <i>Rana Berlandieri</i> and <i>Rana Pipiens</i> ," <i>Eur. J. Biochem. 267</i> :894-900, Federation of European Biochemical Societies (2000)		
	NPL7	Hancock, R.E., <i>et al.</i> , "Cationic Bactericidal Peptides," <i>Adv. Microbial Physiol. 37</i> :135-175, Academic Press Inc. (1995)		
	NPL8	Hancock, R.E., <i>et al.</i> , "The Role of Antimicrobial Peptides in Animal Defenses," <i>Proc. Natl. Acad. Sci. USA. 97</i> :8856-8861, National Academy of Sciences (2000)		
	NPL9	Hetru, C., <i>et al.</i> , "Androctonin, A Hydrophilic Disulphide-Bridged Non-Haemolytic Anti-Microbial Peptide: A Plausible Mode of Action," <i>Biochem. J. 345</i> :653-664, Portland Press Ltd. (2000)		
/S.G./	NPL10	Iwanaga, S., <i>et al.</i> , "New Types of Clotting Factors and Defense Molecules Found in Horseshoe Crab Hemolymph: Their Structures and Functions," <i>J. Biochem. 123</i> :1-15, The Japanese Biochemical Society (1998)		
Examiner Signature	/Satyanarayan Gudibande/		Date Considered	01/30/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/535,624
				Int'l. Filing Date	November 22, 2002
				First Named Inventor	In-Hee LEE
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	2393.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
/S.G./	NPL11	Jang, W. S., <i>et al.</i> , "Halocidin: A New Antimicrobial Peptide from Hemocytes of the Solitary Tunicate, <i>Halocynthia Aurantium</i> ," <i>FEBS Lett.</i> 521:81-86, Elsevier Science B.V. (May 2002)	
	NPL12	Krause, A., <i>et al.</i> , "LEAP-1, A Novel Highly Disulfide-Bonded Human Peptide, Exhibits Antimicrobial Activity," <i>FEBS Lett.</i> 480:147-150, Elsevier Science B.V. (2000)	
	NPL13	Lee, I. H., <i>et al.</i> , "Styelins, Broad-Spectrum Antimicrobial Peptides from the Solitary Tunicate, <i>Styela clava</i> ," <i>Comp. Biochem. Physiol. B Biochem. Mol. Biol.</i> 118B:515-521, Elsevier Science Inc. (1997)	
	NPL14	Lee, I. H., <i>et al.</i> , "Clavanins, $\alpha$ -helical Antimicrobial Peptides from Tunicate Hemocytes," <i>FEBS Lett.</i> 400:158-162, Elsevier Science B.V. (1997)	
	NPL15	Lee, I. H., <i>et al.</i> , "Effects of pH and Salinity on the Antimicrobial Properties of Clavanins," <i>Infection and Immunity.</i> 65:2898-2903, American Society for Microbiology (1997)	
	NPL16	Lee, I. H., <i>et al.</i> , "Dicynthaurin: An Antimicrobial Peptide from Hemocytes of the Solitary Tunicate, <i>Halocynthia aurantium</i> ," <i>Biochim. Biophys. Acta.</i> 1527:141-148, Elsevier Science B.V. (May 2001)	
	NPL17	Lehrer, R. I., <i>et al.</i> , "DEFENSINS: Antimicrobial and Cytotoxic Peptides of Mammalian Cells," <i>Annu. Rev. Immunol.</i> 11:105-128, Annual Reviews Inc. (1993)	
	NPL18	O'Neil, D. A., <i>et al.</i> , "Expression and Regulation of the Human $\beta$ -Defensins hBD-1 and hBD-2 in Intestinal Epithelium," <i>J. Immunol.</i> 163:6718-6724, The American Association of Immunologists (1999)	
	NPL19	Piers, K. L., <i>et al.</i> , "Improvement of Outer Membrane-Permeabilizing and Lipopolysaccharide-Binding Activities of an Antimicrobial Cationic Peptide by C-Terminal Modification," <i>Antimicrob. Agents Chemother.</i> 38:2311-2316, The American Society for Microbiology (1994)	
/S.G./	NPL20	Romeo, D., <i>et al.</i> , "Structure and Bactericidal Activity of an Antibiotic Dodecapeptide Purified from Bovine Neutrophils," <i>J. Biol. Chem.</i> 263:9573-9575, The American Society for Biochemistry and Molecular Biology (1988)	

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/30/2008
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/535,624
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Int'l. Filing Date	November 22, 2002
				First Named Inventor	In-Hee LEE
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2393.0010000/JUK/WBC
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
/S.G./	NPL21	Taylor, S. W., <i>et al.</i> , "Styelin D, an Extensively Modified Antimicrobial Peptide from Ascidian Hemocytes," <i>J. Biol. Chem.</i> 275:38417-38426, The American Society for Biochemistry and Molecular Biology (2000)	
	NPL22	Zhang, L., <i>et al.</i> , "Interaction of Cationic Antimicrobial Peptides with Model Membranes," <i>J. Biol. Chem.</i> 276:35714-35722, The American Society for Biochemistry and Molecular Biology, Inc. (July 2001)	
	NPL23	Zhao, C., <i>et al.</i> , "cDNA Cloning of Clavanins: Antimicrobial Peptides of Tunicate Hemocytes," <i>FEBS Lett.</i> 410:490-492, Elsevier Science B.V. (1997)	
/S.G./	NPL24	Zhao, C., <i>et al.</i> , "cDNA Cloning of Three Cecropin-Like Antimicrobial Peptides (Styelinins) from the Tunicate, <i>Styela clava</i> ," <i>FEBS Lett.</i> 412:144-148, Elsevier Science B.V. (1997)	

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/30/2008
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.